Olivia Vizier

On the same day that Cambridge, MA-based Kymera Therapeutics unveiled a $102 million round to enter into development phase, Nurix said it has raised $120 million to do the same out of San Francisco’s Mission Bay.

When it comes to fighting rare diseases, the biggest barrier to overcome is often the lack of knowledge around the condition. A free genetic test is hoping to combat this and speed up drug development in inherited retinal diseases.

Motus GI is moving its corporate headquarters from Fort Lauderdale, Fla., to the greater Boston area in the second quarter of this year to support commercial efforts for its Pure-Vu colon cleansing system. The new headquarters will be in Norwood, Mass., closer to major medical device hubs, giving the company access to a bigger talent

Last month, OSE Immunotherapeutics SA reported a new collaboration agreement with MAbSilico, which is based in Tours, France. The companies plan to use artificial intelligence (AI)-based solutions for therapeutic antibody drug development.

In a “groundbreaking” preclinical study using the healing power of the body’s own immune system to treat human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC), biopharmaceutical Cue Biopharma Inc. says it has demonstrated the ability of its lead biologic candidate, CUE-101, to activate tumor antigen specific antitumor immunity right on target.

Recently, Diasome Pharmaceuticals announced positive results from its Phase 2 OPTI-1 study on the efficacy of its hepatocyte directed vesicle (HDV) technology for preventing low blood sugar in patients with type 1 diabetes. The study results showed that this liver-targeted insulin may allow patients to reduce the amount of time they spend in hypoglycemia by using HDV technology and optimizing their relative basal and

Long-lasting treatments for invasive fungal disease are becoming ever more necessary but there are many challenges to overcome in drug development. Natalie Healey talks to Cidara Therapeutics about finding safe and effective medicines in this space.

In the world of Longevity start-ups, it’s amazing how often we speak to founders who have a genuine interest in making a difference – often due to very personal experiences. Brad Margus, CEO of brain disease biopharma firm Cerevance, is a perfect example.

Synaptive Medical Inc., of Toronto, has secured Health Canada’s approval for Evry, the company’s superconducting head magnetic resonance imaging (MRI) system. The Evry system aims to provide imaging directly at the point of care in areas outside diagnostic imaging departments.

Drug Target Review’s Hannah Balfour spoke with Dr Nicolas Poirier, the Chief Scientific Officer (CSO) of OSE Immunotherapeutics, to understand their novel approach to targeting and treating autoimmune diseases; using immunology to rebalance the immune system.

Park Slope resident Zach Becker loves “Star Wars” and superheroes just like any other nine-year old. However, for much of his young life, Zach has been living with a rare and incurable disease that has kept him in and out of hospitals.

Drug Target Review spoke with CUE Biopharma’s President and CSO to find out how and why they created the ImmunoSTAT platform and the ways it may benefit drug design in the future.

RNA interference (RNAi), sometimes called gene silencing, is an approach to therapeutics in certain diseases that are caused by the production of abnormal proteins or an overproduction of proteins, which can be treated by turning off or silencing the gene. One of the companies working on the cutting edge of this field is Pasadena, California-based Arrowhead

The first wave of a new class of anti-aging drugs have begun human testing. These drugs won’t let you live longer (yet) but aim to treat specific ailments by slowing or reversing a fundamental process of aging. The drugs are called senolytics—they work by removing certain cells that accumulate as we age.

Rezafungin is a novel molecule in the echinocandin class of antifungals, which its developer Cidara believes will be an improvement among current fungal infections treatments. Rezafungin is being developed as a first-line treatment of candidemia and invasive candidiasis.

Zach, his family and other people suffering from rare diseases will be guests of honor at an event commemorating Rare Disease Day on Leap Day – the rarest day of the year – at Carnegie Hall. Rocket Pharmaceuticals, Inc., a company that researches genetic solutions for diseases like Zach’s, is organizing the event for the

Q: Your experimental protocol was given as third-line treatment, is that correct? Most patients were on their third line of treatment, but inclusion criteria were beyond first-line standard of care.

A number of ingestible technologies have been developed for the diagnosis of gastrointestinal (GI) diseases, including the use of conventional tools, such as endoscopy, radiological imaging, or biochemical tests. Ingestible diagnostics are particularly useful for the exploration of the small bowelii, since gastroscopy can only reach a limited area of the small intestine and alternative

“Their Phase I data was stellar, great Phase I, and then they had this Phase II that failed primarily because they added the wrong drug,” Asher Nathan, CEO and co-founder of NeoTX, told Endpoints News as he unveils $45 million in new financing.

A look into Cue Biopharma’s engineering-centric approach to in vivo tumor antigen specific T cell activation. Late last month, Cue Biopharma shared preclinical and translational data supporting the therapeutic potential of CUE-101 in HPV16-related malignancies.

French companies OSE Immunotherapeutics and MAbSilico are teaming up to drive the discovery of new antibody drugs using artificial intelligence. The three-year partnership will use artificial intelligence, or AI, in six programs designed to accelerate the development of therapeutic monoclonal antibodies (mAbs) that can target cancer and autoimmune diseases.

Jersey City-based Scynexis Inc., a biotechnology company delivering therapies for difficult-to-treat and often life-threatening infections, said Thursday it completed patient enrollment, ahead of schedule, in its global Phase 3 VANISH-306 study to evaluate the safety and efficacy of oral ibrexafungerp as a treatment for women with vulvovaginal candidiasis (VVC), commonly referred to as vaginal yeast infection.